About Areteia Therapeutics
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-A
Global Headquarters
Bernardsville, United States
Year Founded
2021
Team Size
11-50
Tracked Since
Oct 1, 2026
Web & Domain Identity
Official Website
areteiatx.com
Domain Registered Date
Apr 8, 2022
Social & Network Presence
X / Twitter Profile
Not linked
LinkedIn Corporate
Not linked
Company Milestones & Timeline
- Capital Raise
Raised $75,000,000 · Series-A
fundraisingfox.com
- Milestone
Website domain registered
areteiatx.com
- Milestone
Company founded
Bernardsville, United States
Investors & Backers
Access Biotechnology
ARCH Venture Partners
Bain Capital Life Sciences
GV
Marshall Wace
Maverick Capital
Population Health Partners
Sanofi
Saturn Partners
Viking Global Investors
Funding History
Series-A
· Feb 13, 2024
$75,000,000 fundraisingfox.com
Founders & Leadership
Calman Prussin
Senior Vice President, Chief Scientific Officer
Work email & phone locked
Unlock →
Christopher Courts
Founder
Work email & phone locked
Unlock →
Eric Bradford
Chief Medical Officer
Work email & phone locked
Unlock →
Jorge Bartolome
Founder
Work email & phone locked
Unlock →
Mark Kreston
SVP & Chief Commercial Officer
Work email & phone locked
Unlock →
Peter Wijngaard
Chief Development Officer
Work email & phone locked
Unlock →
Robin Walker
Chief Legal Officer and Corporate Secretary
Work email & phone locked
Unlock →
Whit Bernard
Founder
Work email & phone locked
Unlock →
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026